Genfit S.A. (FRA:XUPB)

Germany flag Germany · Delayed Price · Currency is EUR
4.980
-0.070 (-1.39%)
At close: Jan 9, 2026
47.34%
Market Cap264.41M
Revenue (ttm)45.13M
Net Income (ttm)-38.76M
Shares Outn/a
EPS (ttm)-0.81
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume80
Open4.980
Previous Close5.050
Day's Range4.980 - 4.980
52-Week Range2.780 - 5.350
Betan/a
RSI57.81
Earnings DateDec 23, 2025

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 180
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol XUPB
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.